LAVA Therapeutics N.V. (LVTX) Financials

LVTX Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 117.5 million 59.7 million
2023-06-30 133.2 million 63.8 million
2023-03-31 156.3 million 62.6 million
2022-12-31 153.9 million 61.6 million

LVTX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -7.9 million 978187
2023-06-30 -14.4 million 1.7 million
2023-03-31 38.7 million 987546
2022-12-31 38.1 million 972293

LVTX Net Income

No data available :(

LVTX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 110.8 million - 1.3 million
2023-06-30 122.2 million - 2.2 million
2023-03-31 144.8 million - 2.3 million
2022-12-31 142.6 million - 869269

LVTX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 27.8 million
2023-06-30 28.6 million
2023-03-31 28.3 million
2022-12-31 27.8 million

LVTX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 6351 8.4 million 3.0 million -
2023-06-30 243562 13.7 million 4.0 million -
2023-03-31 288851 11.4 million 4.0 million -
2022-12-31 284390 11.3 million 4.0 million -

LVTX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 56108 10586
2023-06-30 5.6 million 2.6 million
2023-03-31 2.9 million 10.7 million
2022-12-31 2.8 million -

LVTX

Price: $2.73

52 week price:
1.13
6.47

Earnings Per Share: -1.57 USD

P/E Ratio: -0.90

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 12191

Market Capitalization: 81.8 million

Links: